Glenmark Pharmaceuticals is a name Indian investors know well, and its recent work on cancer drugs has made its stock price soar. By creating new medicines and signing big deals with global companies, Glenmark is boosting its reputation and share value. Here’s a simple look at how its cancer drug innovations are driving its stock price, written for Indian audiences.
New Cancer Drugs: A Game-Changer
Glenmark is working on cutting-edge medicines to fight cancer, which is a major health issue in India and worldwide. One of its key drugs, ISB 2001, is in clinical trials to treat multiple myeloma, a type of blood cancer. Another drug, Tevimbra (tislelizumab), was launched in India in June 2025 to treat lung and esophageal cancers. These drugs are special because they use advanced technology to help the body fight cancer cells better. When Glenmark announces progress on these drugs, investors get excited, and the stock price often rises. For example, after launching Tevimbra, the stock jumped nearly 3% to ₹1,728 in a day.
Big Global Deals Boost Confidence
Glenmark’s cancer drugs are catching the attention of global giants. In July 2025, its subsidiary, Ichnos Glenmark Innovation, signed a $2 billion deal with AbbVie for ISB 2001. This included a $700 million upfront payment and up to $1.225 billion in future payments. Such deals show that global companies trust Glenmark’s innovations, which makes investors more confident. After this deal was announced, Glenmark’s stock hit a 52-week high of ₹2,286, jumping 10% in a single day. These partnerships prove Glenmark’s drugs have huge potential, pushing its stock value higher.
Strong Financials Support Stock Growth
Glenmark’s focus on cancer drugs is also improving its finances, which helps its stock price. In the financial year 2024-25, the company’s revenue grew by 12.8% to ₹13,321 crore, and its profit reached ₹1,047 crore, a big turnaround from a loss the previous year. These strong results, partly driven by its cancer drug progress, make investors believe in Glenmark’s future. A healthier balance sheet means the company can invest more in research, which keeps the stock trending upward.
Why It Matters to Investors
For Indian investors, Glenmark’s cancer drug innovations are exciting because they show the company is a leader in a growing field. Cancer treatment is in high demand, and Glenmark’s new drugs meet this need. The company’s ability to partner with global firms and earn big payments adds to its value. Plus, its stock has grown 34.94% in the last 12 months, making it attractive for those looking to invest in pharma.
In short, Glenmark’s work on cancer drugs like ISB 2001 and Tevimbra, combined with global deals and strong profits, is driving its stock price higher. For Indian audiences, this means Glenmark is not just a pharma company but a smart investment choice in a world where healthcare innovation matters.
Last Updated on: Friday, July 11, 2025 9:20 pm by Deepak Goud Kondakal | Published by: Deepak Goud Kondakal on Friday, July 11, 2025, 9:20 pm | News Categories: Business
About Us: NewsTrail covers the latest News on Current News, Business, Sports, Tech, Entertainment, Lifestyle, Automobiles, and more, led by Editor-in-Chief Ankur Srivastava. Stay connected on Facebook, Instagram, LinkedIn, X (formerly Twitter), Google News, and Whatsapp Channel.
Disclaimer: At NewsTrail, we are committed to providing accurate, reliable, and thoroughly verified information, sourced from trusted media outlets. For more details, please visit our About, Disclaimer, and Privacy Policy pages. If you have any questions, feedback, or concerns, feel free to contact us through email.
Contact Us: newstrail4@gmail.com
About The Author
